Novo Nordisk A/S (NYSE:NVO) Position Boosted by Cynosure Group LLC

Cynosure Group LLC increased its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 246.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,710 shares of the company's stock after buying an additional 19,003 shares during the period. Cynosure Group LLC's holdings in Novo Nordisk A/S were worth $2,298,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of NVO. Center for Financial Planning Inc. lifted its holdings in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after acquiring an additional 123 shares during the period. Dunhill Financial LLC raised its stake in Novo Nordisk A/S by 196.8% during the third quarter. Dunhill Financial LLC now owns 469 shares of the company's stock worth $56,000 after purchasing an additional 311 shares during the period. Albion Financial Group UT boosted its holdings in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after purchasing an additional 278 shares during the last quarter. Hager Investment Management Services LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at $46,000. Finally, Sound Income Strategies LLC increased its holdings in shares of Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock worth $46,000 after buying an additional 243 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on NVO shares. Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Finally, Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Moderate Buy" and an average target price of $145.25.

Novo Nordisk A/S Stock Down 6.7 %

Novo Nordisk A/S stock traded down $4.52 during midday trading on Friday, hitting $62.58. 10,847,371 shares of the stock were exchanged, compared to its average volume of 5,641,320. Novo Nordisk A/S has a 1 year low of $62.37 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The firm has a market cap of $280.84 billion, a P/E ratio of 19.02, a P/E/G ratio of 0.90 and a beta of 0.61. The company has a 50 day moving average price of $80.85 and a two-hundred day moving average price of $96.75.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S's dividend payout ratio is 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.